The shares of ‘Novo Nordisk’ are growing, encouraged by the expectation of the release of new information regarding the active ingredient of Ozempic and its ability to lower heart threats.
The Danish pharmaceutical leader is preparing to present its conclusions at the American College of Cardiology’s Scientific Session & Expo, planned for March 29-31. The report will explore the influence of semaglutide on cardiovascular threat decrease across different ailments, including type 2 diabetes, obesity, peripheral artery disease, and chronic kidney disease. Intel Shares Surge as New CEO Gelsinger Plans Shake-Up
This good message has assisted Novo Nordisk in recovering some area after a current obstacle. Last week, the company’s shares decreased following frustrating results from a Phase 3 test of its speculative weight-loss medicine, CagriSema. While patients taking CagriSema experienced an average weight loss of 15.7% over 68 weeks, it failed to meet the company’s enthusiastic 25% target.
Despite Monday’s increase, Novo Nordisk’s stock has encountered difficulties. While it’s up in intraday trading, the stock has seen a decrease of approximately 40% over the past year.
